Introduction
Advances in cancer treatment are significantly improving patient survival, in many cases transforming cancers with a poor prognosis into manageable chronic diseases. 1 Worldwide, there are more than 32 million individuals living with cancer. 2 Even patients with advanced disease can have extended survival with newer treatments. 3, 4 Despite therapeutic advances, patients surviving over the long-term face a host of challenges, such as symptom burden, treatment-related side effects, diminished quality of life (QoL), comorbid conditions, and economic losses. 1, [5] [6] [7] [8] [9] [10] [11] Substantial burdens may also be placed on patients' informal caregivers and families. 10, [12] [13] [14] [15] [16] [17] [18] Such issues have sparked interest in the long-term impact of cancer on patients. 1, 19 It has been recommended that studies examine not only how long patients live, but also how well they survive. 7 Although some recently introduced therapies have the potential to substantially prolong life after treatment discontinuation even in advanced solid tumors, 3,4,20 information related to the quality of this prolonged survival period is lacking. Traditional trial endpoints (e.g., median overall survival [OS] , median progression-free survival, objective response rate, and adverse events), which are usually assessed only for a few months from last treatment, tell us little about the quality of long-term survival. The nature of patient populations (eg limited life expectancy for many tumor types) and characteristics of trial designs tend not to fully capture the survivorship experience since they are typically only employed during the treatment phase and may not sufficiently probe all pertinent areas of concern to patients such as life satisfaction, identity, self-esteem, confidence with appearance, and social support.
To address such data gaps, we propose a new concept termed "quality of survival" (QoS), the scope of which extends beyond traditional metrics and takes into account both the extension of life and the quality of that prolonged survival across the entire cancer continuum. We developed a QoS concept map first via a targeted landscape literature review and later investigated its potential utility through interviews with patients, clinicians, and payers. This framework was discussed in the context of two relevant tumor types, metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, which historically have had 5-year survival rates of only 2% 21 and 15% to 20%, 22 respectively.
Methods

Literature-based landscape research
An exploratory literature-based landscape review investigated cancer survival or survivorship and identified any related research, data, and gaps in the field. Peer reviewed and non-peerreviewed literature was identified. An electronic database search collected published articles and an additional web-based search retrieved treatment guidelines, disease forums, and patient advocacy association web sites (Table 1) . Due to the exploratory nature of the research, an iterative approach was taken rather than a formal search strategy which is required for a structured literature review. English language material was retrieved and reviewed in November 2013.
Outputs were used to support the development of a preliminary QoS concept map, which was ratified and adapted further -based on physician and payer insights. We did not test the QoS map directly with patients because the goal was to learn about their experiences and expectations, without presenting preformed ideas. The usefulness and meaningfulness of the QoS map in practice was tested with physicians and payers.
Patient Interviews
Thirty-five patients (20 with metastatic NSCLC from the United States and 15 with metastatic melanoma from Canada; see eTable 1 in the Supplement) were interviewed. This number was considered sufficient to achieve saturation in each indication. 23 Patients were recruited through partner agencies and face-to-face or telephone interviews were conducted. Patients were ≥18 years of age, had a diagnosis of metastatic NSCLC or metastatic melanoma, and were currently 
Clinician Interviews
Forty medical and radiation oncologists specializing in metastatic NSCLC or metastatic melanoma in both the community and academic sectors from the United States, the United Kingdom, France, and Germany (5 metastatic NSCLC and 5 metastatic melanoma specialists per country; see eTable 2 in the supplement) were interviewed. Clinicians were recruited via partner market research agencies in each country. This number was considered robust for qualitative research. 23 Clinicians were required to see at least two patients with metastatic NSCLC or metastatic melanoma per week (8-10 patients per month). Academic clinicians were required to spend at least 50% of their time treating patients.
Clinician interviews consisted of one-hour, semi-structured, telephone conversations based on an interview guide with open-ended, unbiased questions (see clinician interview guide in the Supplement). Interviews were coded according to core themes using Atlas.ti software version 7
(Berlin: ATLAS.ti Scientific Software Development GmbH; 2013). Explored themes included: (1) disease presentation in metastatic NSCLC and metastatic melanoma; (2) disease communication, education, and support; (3) care plan drivers and decision-making; (4) treatment drivers and decision-making; (5) long-term survivorship; and (6) QoS concept map and concept statements. The term "survival" was used during the interviews and in the concept map as a generic term that indicated the patient is alive.
Payer Interviews
Semi-structured telephone interviews (see payer interview guide in the Supplement) were 
Results
Literature-based landscape research
The literature-based landscape review showed a growing awareness of the long-term impact of cancer on patients and the importance of assessing long-term experience. 24 ) hope to achieve a return to/preservation of "normality" with regard to functioning and activities of daily living (i.e., maintenance of QoL). The primary goal of treatment for melanoma patients was less about a return to/preservation of normality but to be cured (7/15 [47%]), implying that melanoma patients do not experience impacts to the same extent as NSCLC patients. The most reported factor in defining a "good day" was being able to participate in usual activities (Figure 2A ), while that in defining a "bad day" was poor symptom control ( Figure 2B ). Several impacts were reported by NSCLC ( Figure 3A ) and melanoma ( Figure 3B) Half of NSCLC patients (50% [10/20] ) largely had realistic expectations that their disease/treatment journey would be long and they anticipated multiple and long-term treatment cycles to manage, but not "cure", their disease. Some NSCLC patients (20% [4/20] ), however, did expect to recover and used terms such as "remission", "be cancer free", and "beat the cancer". clinically meaningful, applied within a multidisciplinary approach, broadly measured across diseases, used as a clinical trial endpoint, and related to specific time frames.
Clinician interviews
The preliminary QoS concept framework ( Figure 1 ) developed based on the literature research was shared with the clinicians during interviews. Clinicians were positive about this map and few suggested changes. They generally felt that the terminology and layout of the map were appropriate; 14 (35%) were happy with the terminology, reporting it as "simple,"
"straightforward," "appropriate," and "understandable." Two clinicians (5%) disliked the term "cost", reporting it sounded negative. One clinician (3%) suggested changing the wording to "economic burden". Three clinicians (8%) felt that the term QoS needed to be defined. example, an increase in survival beyond weeks/months is increasingly being required to demonstrate value (e.g., in metastatic lung cancer, improved survival by a third of patients receiving standard of care; in metastatic melanoma, a long-term remission rate of 40%).
Payer interviews
However, a shift in mind-set to survival with improved QoL is occurring. The terminology "living with cancer" held value as it demonstrated that cure cannot be guaranteed, but that the aim is to extend life while improving QoL. Side effects tended to be considered following efficacy and Some payers noted that although the concept would not be the primary criteria for decisionmaking, it could aid communication between payer groups, and may help communicate different QoS aspects relevant to the patient.
Discussion
The literature-based landscape research and patient, clinician, and payer interviews supported the development of a QoS concept map. As the literature search was exploratory in nature, the authors acknowledge that some gaps in the evidence may exist. However, recently published literature is consistent with our landscape research, describing the challenges faced by cancer patients who survive over the long-term and the need to address such challenges. [36] [37] [38] [39] Although the literature review highlights increasing interest in the quality of extended survival in cancer, the focus remains on QoL in the traditional sense. Consequently, many areas of concern to patients are not measured, including physical discomfort, emotional strain, economic burden, day-to-day function, and impacts on caregivers and families. In the interviews, patients reported evaluating whether a treatment's benefits are justified. 43 The use of a more patient-centric metric of long-term survival could facilitate shared decision making between patients and physicians, potentially leading to increased value-concordant treatment decisions and improving patient satisfaction with their long-term care.
Although the QoS concept map has been supported by our study, additional research is required to further describe each domain. Survival, for example, can be delineated in various ways (e.g., time alive since diagnosis or therapy completion, time without disease progression, or time in complete remission). Clinicians in our study spoke about survival, but did not specify how it should be measured. The distinction between "survival" and "survivorship" is also not clear, with an on-going debate over whether "survivor" is an appropriate label throughout the cancer continuum. 44, 45 Patients and clinicians may also differ on this point. The definition of long-term survival also varies according to tumor type and prognosis.
While QoS can be applied to all tumor types, the concept framework may be most useful for those cancers with more favorable prognoses, allowing QoS to be assessed across the cancer continuum. This map is flexible enough to be used for patients who continue on or have ended treatment. With the emergence of more effective treatments, the QoS concept may become useful in tumors previously with limited survival potential (e.g., advanced melanoma and NSCLC). The QoS concept should be validated in various tumor types.
Educational resources may be required to elucidate QoS dimensions most relevant to patients at each step of the cancer care continuum. Clinician did not have recommendations about QoSspecific PRO measures. Formulating a standardized QoS metric is a challenging next step. As noted in the landscape review, many of the QoS concepts are multidimensional and could be measured by incorporating some existing PRO measures and survival endpoints, rather than developing entirely new instruments. Finally, it was agreed that the concept map should be underpinned with both trial data and real-world data.
The need for an accepted integrated QoS framework has been documented here. The QoS map could be easily applied across tumor types and treatment approaches. While we found similar interest and opinions from interviews of a small group of patients, clinicians, and payers, findings should be confirmed with larger and diverse populations, with the ultimate goal of application in real-life practice.
Acknowledgments
The authors wish to acknowledge Lauren Walrath, formerly at Bristol-Myers Squibb, and Jessica Costello, Laura Grant, Rebecca Hall, Louise Heron, Rhianna Miles, and Nicola
Williamson at Adelphi Values for their work in the design, collection, and interpretation of evidence. Bristol-Myers Squibb, the study sponsor, was involved in the design and conduct of
